Electronic ISSN 2287-0237



  1. Carpenter BD, Xiong C, Porensky EK, et al. Reaction to a dementia diagnosis in individuals with Alzheimer’s disease and mild Cognitive Impairment. J Am Geriatr Soc 2008;56:405-12.
  2. Hort J, O’Brien JT, Gainotti G, et al. EFNS guidelines  for the diagnosis and management of Alzheimer’s disease. Eur J Neurol  2010;17:1236-48.
  3. Tartaglia MC, Rosen HJ, Miller BL. Neuroimaging in dementia. Neurotherapeutics 2011;8:82-92.
  4. Cummings JL. Alzheimer’s disease.N Engl J Med 2004;351:56-67.
  5. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS- ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology  1984;34:939-44.
  6. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol  2007;6:734-46.
  7. Scheltens P. Imaging in Alzheimer’s disease. Dialogues Clin Neurosci  2009;11:191-9.
  8. Gelosa G, Brooks DJ. The prognostic value of amyloid imaging. Eur J Nucl Med Mol Imaging  2012;39:1207-19.
  9. Mori T, Maeda J, Shimada H, et al. Molecular imaging of dementia. Psychogeriatrics  2012;12:106-14.
  10. Forsberg A, Engler H, Almkvist O, et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging  2008;29:1456-65.
  11. Drzezga A, Grimmer T, Riemenschneider M, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med  2005;46:1625-32.
  12. Small GW, Siddarth P, Burggren AC, et al. Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia.Arch Gen Psychiatry 2009;66:81-7.
  13. Bloudek LM, Spackman DE, Blankenburg M, et al. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer’s disease. J Alzheimers Dis 2011; 26:627-45.
  14. Hoffman JM, Welsh-Bohmer KA, Hanson M, et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 2000;41:1920-8.
  15. Wolk DA, Price JC, Madeira C, et al. Amyloid imaging in dementias with atypical presentation. Alzheimers Dement  2012;8:389-98.
  16. Silverman DH, Small GW, Phelps ME. Clinical Value of Neuroimaging in the Diagnosis of Dementia. Sensitivity and Specificity of Regional Cerebral Metabolic and  Other Parameters for Early Identification of Alzheimer’s Disease. Clin Positron Imaging  1999;2:119-30.
  17. Small GW, Bookheimer SY, Thompson PM, et al. Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol  2008;7:161-72.
  18. Klein JC, Eggers C, Kalbe E, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology  2010;74:885-92.
  19. Nestor PJ, Caine D, Fryer TD, et al. The topography of metabolic deficits in posterior cortical atrophy (the visual variant of Alzheimer’s disease) with FDG-PET. J Neurol Neurosurg Psychiatry  2003;74:1521-9.
  20. Shimada A, Hashimoto H, Kawabe J, et al. Evaluation of therapeutic response to donepezil by positron emission tomography. Osaka City Med J  2011;57:11-9.
  21. Martin-Moreno AM, Brera B, Spuch C, et al. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation 2012;9:8.
  22. Forster S, Buschert VC, Teipel SJ, et al. Effects of a 6-month cognitive intervention on brain metabolism in patients with amnestic MCI and mild Alzheimer’s disease. J Alzheimers Dis 2011;26:337-48.